Deborah Gordon - Vice President, Investor Relations Rohin Patel - JPMorgan Josh Jennings - TD Cowen Sam Eiber - BTIG Good afternoon, ladies and gentlemen, and welcome to the Insulet Corporation Fourth Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode. Later we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions] As a reminder, this conference call is being recorded. With me today are Jim Hollingshead President and Ch ...

Insulet (PODD) reported $509.8 million in revenue for the quarter ended December 2023, representing a year-over-year increase of 37.9%. EPS of $1.40 for the same period compares to $0.55 a year ago.The reported revenue represents a surprise of +10.79% over the Zacks Consensus Estimate of $460.17 million. With the consensus EPS estimate being $0.67, the EPS surprise was +108.96%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall St ...

Insulet (PODD) came out with quarterly earnings of $1.40 per share, beating the Zacks Consensus Estimate of $0.67 per share. This compares to earnings of $0.55 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 108.96%. A quarter ago, it was expected that this maker of insulin infusion systems would post earnings of $0.40 per share when it actually produced earnings of $0.71, delivering a surprise of 77.50%.Over the last four qua ...

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months and full year ended December 31, 2023. Full Year Financial Highlights: Full year 2023 revenue of $1.7 billion, up 30.0%, or 29.6% in constant currency, compared to $1.3 billion in the prior year, exceeds the guidance range of 26% to 27% in constant currency. Full year ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-33462 INSULET CORPORATION (Exact name of Registrant as specified in its charter) Delaware 04-3523891 (State or Other Jurisdict ...

Insulet Reports Full Year 2023 Revenue Increase of 30% (30% constant currency ) and Fourth Quarter 2023 Revenue Increase of 38% Year-Over-Year (37% constant currency) 1 Represents 8th Consecutive Year of 20% or More Constant Currency Revenue Growth ACTON, Mass. - February 22, 2024 - Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of products, today announced financial results for the three months and full year ended De ...

Insulet Corporation (PODD) is poised to gain in the coming quarters owing to the strength of its revolutionary offering, the Omnipod 5 Automated Insulin Delivery (“AID”) system. The flourishing diabetes market raises optimism for the company’s operations. A strong solvent balance sheet is highly encouraging.  Meanwhile, elevated costs and the impact of macroeconomic pressures may adversely affect Insulet’s results of operations.In the past year, this Zacks Rank #3 (Hold) stock has decreased 35.6% against th ...

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at The Raymond James & Associates 45th Annual Institutional Investors Conference in Orlando on Tuesday, March 5, 2024 at 11:35 a.m. (Eastern Time). To listen to the live audio webcast of the presentation, please visit investors.insulet.com/events. A replay of the webcast will also be available fol ...

Insulet Corporation (PODD) recently received CE mark approval under the European Medical Device Regulation for the added compatibility of the Abbott Laboratories’ (ABT) FreeStyle Libre 2 Plus sensor with its Omnipod 5 Automated Insulin Delivery System. It is applicable for individuals aged two years and above with type 1 diabetes.The Omnipod 5 System consists of the tubeless Pod enhanced with SmartAdjust Technology and the Omnipod 5 Controller with its integrated Smartbolus Calculator.Insulet expects Omnipo ...

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it has received CE mark approval under the European Medical Device Regulation for the added compatibility of the Abbott FreeStyle Libre 2 Plus sensor with Insulet’s Omnipod 5 Automated Insulin Delivery System for individuals aged two years and older with type 1 diabetes. “The addition of the Abbott FreeStyle ...